Answers are grounded in this paper and cite their sources.
Previous studies have demonstrated in vivo MRS could be an effective approach to assess the metabolite changes in Huntington Disease (HD) patients and models. However, its sensitivity to detect the metabolite abnormality is still in dispute. The metabolic changes in the striatum of transgenic monkeys of HD were investigated with MRS from 12 to 60 months of age here. A progressive and significant reduction of NAA/tCr and NAA/tCho in striatum was observed at 30 and 36 months and old, respectively, suggesting the sensitivity of the in vivo MRS to assess the neurochemical alteration in the evolution of the disease.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: